Clinical trials: Vinorelbine
Breast Cancer
Arsenous Acid for Refractory Triple-Negative Breast Cancer
The primary objective of this study is to assess the progression-free survival (PFS) and safety of arsenous acid in combination with palliative chemotherapy for refractory triple-negative breast cancer following multiple lines of…
- Trial name
- NCT06678048
- Testing
- Arsenous Acid plus Chemotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-sen University
Tumors, Hodgkins Disease
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease
This Phase 1 study will determine the safety, tolerability, and pharmacokinetics of vinorelbine liposomes injection (VLI) in patients with advanced solid tumors, non-Hodgkin's lymphoma, or Hodgkin's disease.
- Conditions
- Tumors, Hodgkins Disease, Non-Hodgkins Lymphoma
- Trial name
- NCT00364676
- Testing
- VLI
- Where
- 3 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Locally Recurrent Breast Cancer, Metastatic Breast Cancer
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens.
- Trial name
- BEACON (NCT01492101)
- Testing
- NKTR-102, Treatment of Physician's Choice (TPC)
- Where
- 153 sites in United States, Belgium and 9 more
- Volunteers
- 852 people
- Sponsor
- Nektar Therapeutics
Metastatic Breast Cancer
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to identify the highest tolerable dose of pyrotinib in combination with vinorelbine and to assess the safety and efficacy of the combination in Patients With HER2-Positive Locally Advanced or…
- Trial name
- NCT03997539
- Testing
- Pyrotinib, Treatment of physician's choice, vinorelbine
- Volunteers
- 256 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
To evaluate the efficacy and safety adebrelimab in Combination with chemotherapy after 3 cycles as neoadjuvant therapy and surgery or chemoradiotherapy based on MDT compared with adebrelimab after chemoradiotherapy in potentially…
- Trial name
- NCT06424899
- Testing
- Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zeng Jian
Prostate Cancer
Vinorelbine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating patients with metastatic…
- Trial name
- NCT00003259
- Testing
- vinorelbine tartrate
- Where
- 10 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Cervical Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the…
- Trial name
- NCT06459180
- Testing
- Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin
- Where
- 240 sites in United States, Argentina and 30 more
- Volunteers
- 686 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
The purpose of this research study is to determine the effects of the combination of bevacizumab, vinorelbine, and trastuzumab on participants and their cancer.
- Trial name
- NCT00670982
- Testing
- bevacizumab, vinorelbine, trastuzumab
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Harold J. Burstein, MD, PhD
Breast Cancer Metastatic, BRCA 1 Gene Mutation
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in…
- Conditions
- Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
- Trial name
- OlympiAD (NCT02000622)
- Testing
- Olaparib, Physician's choice chemotherapy
- Where
- 171 sites in United States, Bulgaria and 17 more
- Volunteers
- 302 people
- Sponsor
- AstraZeneca
Carcinoma, Invasive Ductal, Breast
Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)
It is a phase III trial to explore the efficacy and safety of vinorelbine plus capecitabine (NX) and docetaxel plus capecitabine (TX) as first line treatment followed by capecitabine alone till Progressive Disease(PD).
- Trial name
- NCT01126138
- Testing
- Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine, Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer, Metastatic Cancer
Chemotherapeutic Agents in Brain/Breast
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00795678
- Testing
- capecitabine, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Breast Cancer
A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer
This is a phase II trial of Doxil on day 1 and vinorelbine on days 1 and 2 in women with metastatic breast cancer. Administered every 28 days.
- Trial name
- NCT00159094
- Testing
- Doxil and Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hematology Oncology Consultants
Triple Negative Breast Cancer
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
Triple-negative breast cancer constitutes 15-20% of cases of breast cancer and is defined by the absence of estrogen receptors, progesterone receptors, and overexpression or gene amplification of HER2.
- Trial name
- NCT04745975
- Testing
- Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel, Eribulin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Cervical Cancer Recurrent or Persistent, Palliative Treatment
Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma
This study evauates the global survival of patients following administration of mAb Nimotuzumab hR3 + chemotherapy in the treatment of cervical cancer in first line therapy, after relapsing from chemo-radiotherapy.
- Conditions
- Cervical Cancer Recurrent or Persistent, Palliative Treatment, Monoclonal Antibody in Cervical Cancer Treatment
- Trial name
- NCT02083211
- Testing
- mAb Nimotuzumab
- Where
- Mexico
- Volunteers
- 168 people
- Sponsor
- National Institute of Cancerología
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed…
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT00324805
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 1,169 sites in United States, Canada and 3 more
- Volunteers
- 1,501 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
To determine the safety of administering anakinra plus the physician's chemotherapy choice (TPC) of nab paclitaxel, capecitabine, eribulin, or vinorelbine in patients with metastatic breast cancer (MBC), as well as determining…
- Trial name
- NCT01802970
- Testing
- Anakinra plus Standard of Care
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Breast Cancer
Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer
The study hypothesis is that metronomic treatment is more efficient than standard treatment.
- Trial name
- XeNa (NCT01941771)
- Testing
- Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda), Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- University of Aarhus
Non Small Cell Lung Cancer
Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients
Primary: ·To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer Secondary: ·To evaluate the toxicity of the…
- Trial name
- GON (NCT00271271)
- Testing
- oxaliplatine / gemcitabine / Vinorelbine
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Sanofi
Rhabdomyosarcoma, Recurrent, Refractory
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.
- Trial name
- NCT06816771
- Testing
- pazopanib, TGI chemotherapy, CIV chemotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shandong Cancer Hospital and Institute
Anaplastic Large Cell Lymphoma, Vinorelbine
Vinorelbine for Recurrent ACLC
The purpose of this study is to assess the efficiency and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.
- Trial name
- NCT03397953
- Testing
- Vinorelbine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Children's Cancer Group, China